The use of menopausal hormone therapy after cancer. (May 2022)

• Record Type: Journal Article
• Authors: Brennan, Annabelle; Hickey, Martha
• Is Part Of: Best practice & research. Volume 81(2022)
• Page Start: 22
• Page End: 30
• Publication Date: 2022-05
• Subjects: Menopausal hormone therapy, MHT -- Hormone replacement therapy, HRT -- Endometrial cancer -- Ovarian cancer -- Cervical cancer -- BRCA, Breast cancer; Gynecology -- Periodicals; Obstetrics -- Periodicals; Genital Diseases, Female; Obstetrics; Gynecology; Obstetrics; Periodicals; 618.05
• DOI: 10.1016/j.bpobgyn.2021.11.005
• Languages: English
• ISSNs: 1521-6934

Abstract

Abstract: The changing landscape of gynaecological and breast cancers has involved the development of more targeted and effective therapies, and improved survival. Ultimately, these changes result in an increasing number of women surviving their cancer diagnosis, with increasing emphasis on quality-of-life issues by following treatments. Many of these women experience severe menopausal symptoms associated with cancer treatments, but the hormonal nature of many gynaecological and breast cancers complicates the effective management of these symptoms. Generally, there is a paucity of high-quality data directly examining the safety of menopausal hormone therapy (MHT) following many female cancers, and more research is needed with long term follow-up to ensure the provision of comprehensive, patient-focussed care. This article aims to synthesise and evaluate the current evidence to provide comprehensive yet accessible information to clinicians to help guide treatment decisions about the use of MHT in women, who have experienced, or are at increased risk of, both gynaecological and breast cancers. These treatment decisions should often be made in a multi-disciplinary setting which encourages shared decision-making with patients. Highlights: The use of MHT after endometrial cancer should be individualised; current evidence is limited. MHT is recommended for women experiencing menopause after treatment for cervical cancer. MHT following treatment for ovarian cancer is dependent on histological subtype and tumour grade. A personal history of breast cancer is a contraindication to systemic MHT. MHT is appropriate for women with BRCA 1 or 2 if there is no personal history of breast cancer.